Codexis, Inc. (CDXS)

NASDAQ: CDXS · Real-Time Price · USD
2.240
+0.010 (0.45%)
At close: Jun 16, 2025, 4:00 PM
2.320
+0.080 (3.57%)
After-hours: Jun 16, 2025, 7:45 PM EDT
0.45%
Market Cap 185.57M
Revenue (ttm) 49.82M
Net Income (ttm) -74.46M
Shares Out 82.84M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 519,642
Open 2.260
Previous Close 2.230
Day's Range 2.180 - 2.280
52-Week Range 1.900 - 6.080
Beta 2.53
Analysts Buy
Price Target 11.00 (+391.07%)
Earnings Date Aug 7, 2025

About CDXS

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 22, 2010
Employees 188
Stock Exchange NASDAQ
Ticker Symbol CDXS
Full Company Profile

Financial Performance

In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 391.07% from the latest price.

Price Target
$11.0
(391.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Codexis' Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA

Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases

25 days ago - GlobeNewsWire

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced th...

26 days ago - GlobeNewsWire

Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive O...

4 weeks ago - Seeking Alpha

Codexis Reports First Quarter 2025 Financial Results

Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming ...

4 weeks ago - GlobeNewsWire

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes

5 weeks ago - GlobeNewsWire

Codexis to Report First Quarter 2025 Financial Results on May 14

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...

6 weeks ago - GlobeNewsWire

Codexis Announces Byron Dorgan to Retire from Board of Directors

REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...

2 months ago - GlobeNewsWire

Codexis Announces New Employment Inducement Grants

REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced ...

3 months ago - GlobeNewsWire

Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Execut...

3 months ago - Seeking Alpha

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

4 months ago - GlobeNewsWire

Codexis Appoints Arthur Levin, PhD, to Strategic Advisory Board

REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

4 months ago - GlobeNewsWire

Codexis Appoints Christos Richards to Board of Directors

REDWOOD CITY, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

5 months ago - GlobeNewsWire

Codexis to Participate in Piper Sandler 36th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

7 months ago - GlobeNewsWire

Codexis Unveils Pioneering Enzymatic Synthesis Data to Enable the Future Manufacturing of RNAi Therapeutics

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset— —Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared t...

7 months ago - GlobeNewsWire

Codexis Announces Appointment of Raymond De Vré, PhD, to Board of Directors

REDWOOD CITY, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

7 months ago - GlobeNewsWire

Codexis TIDES Europe Presentations to Feature Next Step in Evolution of Enzymatic Synthesis for RNAi Therapeutics

—Spotlight Presentation to showcase four routes of synthesis of an approved siRNA therapeutic asset— —Joint poster presentation with Bachem to compare Codexis double-stranded RNA ligase to wild-type e...

7 months ago - GlobeNewsWire

Codexis to Participate in Upcoming Healthcare Conferences

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

8 months ago - GlobeNewsWire

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

Codexis, Inc. (CDXS) Q3 2024 Earnings Call Transcript

8 months ago - Seeking Alpha

Codexis Announces Three siRNA Manufacturing Data Presentations at TIDES Europe Annual Meeting

Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platform Oral Presentations to Highlight Results of Customer Collaborations using the ECO Synthesis™ Platfor...

8 months ago - GlobeNewsWire

Codexis to Report Third Quarter 2024 Financial Results on October 31

REDWOOD CITY, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced t...

8 months ago - GlobeNewsWire

Codexis Increases Cash Reserves and Enhances Management Team to Fuel Growth of Company

Company raises $31 million through ATM, bringing cash runway into 2027 New additions to leadership in technical operations, finance and intellectual property prepare Codexis for the next phase of grow...

9 months ago - GlobeNewsWire

Codexis Licenses Genomics Life Science Enzyme Portfolio to Alphazyme LLC, part of Maravai LifeSciences

Non-exclusive license includes HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes for genomics and diagnostic applications Non-exclusive license includes ...

9 months ago - GlobeNewsWire

Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting

REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel dis...

10 months ago - GlobeNewsWire

Codexis Publishes FY2023 Sustainability Disclosures

Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board

10 months ago - GlobeNewsWire

Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript

Codexis, Inc. (NASDAQ:CDXS) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research K...

11 months ago - Seeking Alpha